个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Lin, Ningjing[1] * ; Sun, Xiuhua[2] ; Zhou, Hui[3] ; Zou, Liqun[4] ; Zhou, Keshu[5] ; Liu, Lihong[6] ; Yang, Haiyan[7] ; Hu, Kai[8] ; Cai, Qingqing[9] ; Liu, Yao[10] ; Jin, Jie[11] ; Zhang, Liling[12] ; Li, Wenyu[13] ; Guo, Ye[14] ; Yang, Wei[15] ; Luo, Feng[16] ; Li, Yanyan[16] ; Zhang, Mengqi[16] ; Lu, Feinan[16] ; Song, Yuqin[17] ; Zhu, Jun[18] ;
机构： [1]Beijing Canc Hosp, Dept Lymphat Oncol, Beijing, Peoples R China [2]Dalian Med Univ, Hosp 2, Dalian, Peoples R China [3]Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China [4]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [5]Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Canc Hosp, Zhengzhou, Peoples R China [6]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China [7]Zhejiang Canc Hosp, Dept Lymphat Oncol, Hangzhou, Peoples R China [8]Beijing Boren Hosp, Dept Adult Lymphoma, Beijing, Peoples R China [9]Sun Yat Sen Univ, Canc Cente, Guangzhou, Peoples R China [10]Chongqing Univ, Canc Hosp, Chongqing, Peoples R China [11]Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China [12]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China [13]Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China [14]Shanghai East Hosp, Shanghai, Peoples R China [15]China Med Univ, Dept Hematol, Shengjing Hosp, Shenyang, Peoples R China [16]Overland Pharmaceut, Shanghai, Peoples R China [17]Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China [18]Peking Univ, Canc Hosp, Beijing, Peoples R China
出处：
DOI： 10.1182/blood-2023-173645
ISSN：
语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 血液学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 血液学
JCR分区：
出版当年[2023]版：
Q1 HEMATOLOGY
最新[2023]版：
Q1 HEMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Beijing Canc Hosp, Dept Lymphat Oncol, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Lin Ningjing,Sun Xiuhua,Zhou Hui,et al.Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)[J].BLOOD.2023,142:doi:10.1182/blood-2023-173645.
APA：
Lin, Ningjing,Sun, Xiuhua,Zhou, Hui,Zou, Liqun,Zhou, Keshu...&Zhu, Jun.(2023).Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).BLOOD,142,
MLA：
Lin, Ningjing,et al."Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)".BLOOD 142.(2023)

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号